GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

GRAIL, Inc.NASDAQ: GRAL

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit remains negative

Q2 FY2026 gross profit was -$12.57M, compared with -$17.78M a year earlier. Trailing-twelve-month gross profit was -$17.89M.

Context

  • Gross profit amounted to 42.5% of revenue in FY2025, down 19.6 pp from a year earlier.
  • Gross profit grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$12.57M or moves back toward the trailing-twelve-month quarterly average of -$4.47M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$12.57M-164.3% QoQ
Last fiscal yearDec 2025
-$62.57M+19.8% YoY
LTMJun 2026
-$17.89M+76.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.3%——
1 year+19.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(62.57M) USD
Year-over-year change
+19.8%

Gross Profit vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's LTM Jun 2026 gross profit of -$17.89M is the lowest of the 10 companies compared; the peer median is $309.9M.
  • Its year-over-year change of +76.4% is the 2nd highest of 10, against a peer median of +9.3%.
  • Gross profit amounts to 10.8% of revenue for GRAL, versus a peer median of 65.3%.
GRAL Competitors Peer median
Gross Profit for GRAL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$1.77B +43.1%+60.2%65.3%
GHGuardant Health, Inc.LTM Sep 2026$833.7M +44.9%+29.2%65.2%
MYGNMyriad Genetics, Inc.LTM Mar 2026$580M -0.3%+6.6%70.0%
NEONeoGenomics, Inc.LTM Jun 2026$328.9M +8.7%+14.6%42.9%
WGSGeneDx Holdings Corp.LTM Jun 2026$309.9M +27.3%—68.2%
BLLNBillionToOne, Inc.LTM Jun 2026$283.22M +122.4%—71.3%
CSTLCastle Biosciences, Inc.LTM Mar 2026$261.97M -7.9%+37.5%77.1%
FLGTFulgent Genetics, Inc.LTM Mar 2026$124.02M +9.3%-29.1%38.7%
PSNLPersonalis, Inc.LTM Mar 2026$8.85M -69.0%—13.7%
GRALGRAIL, Inc.LTM Jun 2026-$17.89M +76.4%—10.8%
Peer median (excluding GRAL) $309.9M+9.3%+21.9%65.3%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.61M55.55M93.11M125.6M147.17M
Cost of Revenue114.62M172M188.72M203.62M209.75M
Gross Profit(100M)(116.45M)(95.61M)(78.02M)(62.57M)
Gross Margin-684.4%-209.6%-102.7%-62.1%-42.5%
Research & Development460.21M329.58M338.75M322.38M195.79M
Selling, General & Admin234.06M296.44M362.56M367.82M275.8M
Operating Expenses1.17B5.33B1.42B2.11B471.59M
Depreciation & Amortization58.45M154.76M158.7M158.06M156.34M
EBITDA(1.21B)(587.7M)(638.22M)(610.17M)(378.16M)
EBITDA Margin-8259.0%-1058.0%-685.5%-485.8%-257.0%
Operating Income(1.27B)(5.44B)(1.52B)(2.19B)(534.16M)
Operating Margin-8659.6%-9798.2%-1627.6%-1743.0%-363.0%
Interest Income332K1.74M7.95M26.73M28.65M
Interest Expense00000
Other Income / Expenses90K1.5M7.75M26.8M(341K)
Income Before Tax(1.27B)(5.44B)(1.51B)(2.16B)(534.5M)
Pre-Tax Margin-8659.0%-9795.5%-1619.3%-1721.7%-363.2%
Income Tax Expense(17.48M)(42.29M)(41.95M)(135.36M)(126.15M)
Net Income(1.25B)(5.4B)(1.47B)(2.03B)(408.35M)
Net Margin-8539.4%-9719.3%-1574.2%-1613.9%-277.5%
EPS (Basic)(40.18)(173.87)(47.20)(63.54)(11.11)
EPS (Diluted)(40.18)(173.87)(47.20)(63.54)(11.11)
Weighted Avg Shares31.05M31.05M31.05M31.9M36.75M
Weighted Avg Shares (Diluted)31.05M31.05M31.05M31.9M36.75M

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.